secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001171843-25-000116
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics provides pipeline update; cash at $127M, tovecimig data Q1 2025
--------------------------------------------------------------------------------

- Estimated $127M cash at YE 2024; cash runway expected into Q1 2027.
- Top-line Phase 2/3 data for tovecimig (CTX-009) in BTC expected end of Q1 2025.
- New drug candidate CTX-10726 (PD-1 x VEGF-A bispecific) advancing; IND submission targeted by YE 2025.
- Third dosing cohort fully enrolled for CTX-8371 Phase 1; preliminary data H2 2025.
- Two Phase 2 biomarker trials planned for mid-2025: tovecimig in DLL4+ CRC and CTX-471 in NCAM/CD56+ tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184325000116/0001171843-25-000116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184325000116/f8k_010725.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-000116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer